Clinical trials: Refractory Celiac Disease
Type II Refractory Celiac Disease (RCD-II), In-situ Small Bowel T-cell Lymphoma
Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease
Protocol CELIM-RCD-002 is designed to evaluate the efficacy and safety of AMG 714 for the treatment of adult patients with type II refractory celiac disease (RCD-II), an in-situ small bowel T-cell lymphoma.
- Trial name
- NCT02633020
- Testing
- AMG 714
- Where
- 6 sites in United States, Finland and 3 more
- Volunteers
- 28 people
- Sponsor
- Amgen